Bicara Therapeutics Initiated With a Not Rated at Goldman Sachs

TipRanks16:45 ET

Bicara Therapeutics Reports Strong IPO and Clinical Advancements

TipRanksNov 13 23:43 ET

Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $36

Moomoo NewsNov 13 08:36 ET · Ratings

Stifel Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $47

Moomoo NewsNov 13 08:36 ET · Ratings

Morgan Stanley Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Raises Target Price to $36

Moomoo NewsNov 13 07:35 ET · Ratings

Express News | Bicara Therapeutics Inc : Morgan Stanley Raises Target Price to $36 From $35

ReutersNov 13 05:31 ET